SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

BRONTE, Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.474
AS - Asia 2.081
EU - Europa 715
SA - Sud America 429
Continente sconosciuto - Info sul continente non disponibili 195
AF - Africa 85
OC - Oceania 6
Totale 5.985
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.328
SG - Singapore 679
IT - Italia 391
BD - Bangladesh 387
CN - Cina 323
BR - Brasile 293
VN - Vietnam 204
HK - Hong Kong 189
DE - Germania 73
IN - India 63
CA - Canada 53
MX - Messico 49
AR - Argentina 46
FR - Francia 42
ZA - Sudafrica 39
GB - Regno Unito 34
ID - Indonesia 34
JP - Giappone 34
RU - Federazione Russa 32
FI - Finlandia 30
UA - Ucraina 29
CO - Colombia 25
EC - Ecuador 25
IQ - Iraq 25
TR - Turchia 22
NL - Olanda 20
MY - Malesia 19
ES - Italia 15
JM - Giamaica 15
MA - Marocco 13
PH - Filippine 13
PK - Pakistan 13
VE - Venezuela 13
SA - Arabia Saudita 11
AE - Emirati Arabi Uniti 10
AT - Austria 8
CL - Cile 8
TN - Tunisia 8
NP - Nepal 7
UZ - Uzbekistan 7
AU - Australia 6
BO - Bolivia 6
DZ - Algeria 6
GT - Guatemala 5
IE - Irlanda 5
KG - Kirghizistan 5
PS - Palestinian Territory 5
UY - Uruguay 5
AL - Albania 4
CH - Svizzera 4
JO - Giordania 4
OM - Oman 4
PL - Polonia 4
PY - Paraguay 4
TH - Thailandia 4
TT - Trinidad e Tobago 4
BB - Barbados 3
BG - Bulgaria 3
CI - Costa d'Avorio 3
CR - Costa Rica 3
DO - Repubblica Dominicana 3
EG - Egitto 3
ET - Etiopia 3
IL - Israele 3
LB - Libano 3
LT - Lituania 3
PA - Panama 3
PE - Perù 3
SE - Svezia 3
SN - Senegal 3
AO - Angola 2
AZ - Azerbaigian 2
BH - Bahrain 2
CZ - Repubblica Ceca 2
EE - Estonia 2
GE - Georgia 2
GR - Grecia 2
KE - Kenya 2
KH - Cambogia 2
LV - Lettonia 2
NI - Nicaragua 2
PT - Portogallo 2
SY - Repubblica araba siriana 2
TW - Taiwan 2
AI - Anguilla 1
BS - Bahamas 1
BY - Bielorussia 1
BZ - Belize 1
GA - Gabon 1
HN - Honduras 1
LK - Sri Lanka 1
LY - Libia 1
MD - Moldavia 1
MQ - Martinica 1
MT - Malta 1
MU - Mauritius 1
NO - Norvegia 1
SK - Slovacchia (Repubblica Slovacca) 1
SR - Suriname 1
SV - El Salvador 1
Totale 5.790
Salva come PNG Salva come JPEG
Città #
Santa Clara 458
Singapore 380
San Jose 347
Ashburn 223
Council Bluffs 221
Hong Kong 187
New York 106
Beijing 77
Ho Chi Minh City 73
Los Angeles 53
Milan 44
Hanoi 43
Mexico City 38
Bologna 37
Chicago 35
Tokyo 34
Dallas 31
Rome 28
Buffalo 26
Lauterbourg 23
Lappeenranta 21
São Paulo 21
Jakarta 19
Fairfield 17
Hefei 17
Orem 17
Ferrara 16
Palermo 16
Brooklyn 14
Cambridge 13
London 13
Phoenix 13
Toronto 13
Dhaka 12
Kuala Lumpur 12
Naples 12
Salt Lake City 12
Chennai 11
Da Nang 11
Montreal 11
Munich 11
Baghdad 10
Guayaquil 10
Las Vegas 10
Newark 10
San Francisco 10
Seattle 10
Houston 9
Kingston 9
Brasília 8
Rio de Janeiro 8
Atlanta 7
Bari 7
Curitiba 7
Elk Grove Village 7
Johannesburg 7
Medellín 7
Paris 7
Amsterdam 6
Charlotte 6
City of London 6
Denver 6
Falkenstein 6
Fortaleza 6
Frankfurt am Main 6
Helsinki 6
Indianapolis 6
Salvador 6
Sydney 6
Tashkent 6
Thái Bình 6
Woodbridge 6
Ankara 5
Boardman 5
Caracas 5
Detroit 5
Dublin 5
Forest City 5
Guatemala City 5
Lahore 5
Moscow 5
Philadelphia 5
Quito 5
Wilmington 5
Assago 4
Bangkok 4
Bhopal 4
Bishkek 4
Bogotá 4
Brescia 4
Bình Dương 4
Cali 4
Cleveland 4
Columbus 4
Delhi 4
Figino 4
Florence 4
Haiphong 4
La Paz 4
Manila 4
Totale 3.117
Salva come PNG Salva come JPEG
Nome #
Near-Complete Response to Osimertinib for Advanced Non-Small-Cell Lung Cancer in a Pretreated Patient Bearing Rare Compound Exon 20 Mutation (S768I + V774M): A Case Report 158
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer 135
P3.12.20 VAF of EGFR Mutations in Relation to Early Tumor Shrinkage or Deepness of Response During Osimertinib in NSCLC Patients 113
A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients 109
How much of familial breast cancer risk is currently explained by the known genes? 103
Immune Checkpoint Inhibitors in “Special” NSCLC Populations: A Viable Approach? 102
Wide Next-Generation Sequencing Characterization of Young Adults Non-Small-Cell Lung Cancer Patients 100
The likelihood of being helped or harmed obtained from clinical trial results for cancer therapy: Can it really help? 94
Relationship between imaging‐derived parameters and circulating microRNAs to study the degree of lung involvement in hospitalized geriatric patients with COVID‐19 pneumonia 94
Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors 92
To ablate or not to ablate? Outcomes of local ablative treatments (LAT) for oncogene addicted (OA) oligo-metastatic (OM) non-small cell lung cancer (NSCLC): A systematic review 91
Magnetic Resonance Imaging and 99Tc WBC-SPECT/CT Scanning in Differential Diagnosis between Osteomyelitis and Charcot Neuroarthropathy: A Case Series 87
Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future 85
Concomitant TP53 mutation confers worse prognosis in EGFR-mutated non-small cell lung cancer patients treated with TKIs 83
Chronological age or biological age: What drives the choice of adjuvant treatment in elderly breast cancer patients? 83
The cell line models to study tyrosine kinase inhibitors in non-small cell lung cancer with mutations in the epidermal growth factor receptor: A scoping review 82
The Influence of Myeloid-Derived Suppressor Cell Expansion in Neuroinflammation and Neurodegenerative Diseases 81
High Levels of Circulating Monocytic Myeloid-Derived Suppressive-Like Cells Are Associated With the Primary Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: An Exploratory Analysis 81
Healthcare Costs and Resource Utilisation of Italian Metastatic Non-Small Cell Lung Cancer Patients 80
The prognostic effects of circulating myeloid-derived suppressor cells in non-small cell lung cancer: systematic review and meta-analysis 79
Adjuvant Chemoradiation Therapy in Gastric Cancer: Critically Reviewing the Past and Visualizing the Next Step Forward 78
Are there differences in androgen receptor expression in invasive breast cancer in African (Tanzanian) population in comparison with the Caucasian (Italian) population? 75
Circulating myeloid-derived suppressor cells and survival in prostate cancer patients: systematic review and meta-analysis 72
Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis 72
Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus 71
Real-World Outcomes and Treatments Patterns Prior and after the Introduction of First-Line Immunotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer 70
Androgen receptor in advanced breast cancer: Is it useful to predict the efficacy of anti-estrogen therapy? 69
Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream 69
DNA Methylation-derived biological age and long-term mortality risk in subjects with type 2 diabetes 69
The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy 69
Advances in molecular mechanisms and immunotherapy involving the immune cell-promoted epithelial-to-mesenchymal transition in lung cancer 68
Replicative Senescence-Associated LINE1 Methylation and LINE1-Alu Expression Levels in Human Endothelial Cells 68
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects 67
Anti-angiogenic drugs for second-line treatment of NSCLC patients: Just new pawns on the chessboard? 66
The great need to overcome osimertinib resistance in advanced non-small cell lung cancer: from combination strategies to fourth-generation tyrosine kinase inhibitors 66
ALK and crizotinib: After the honeymoon...what else? Resistance mechanisms and new therapies to overcome it 66
Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors 66
Analysis of Germline gene copy number variants of patients with sporadic pancreatic adenocarcinoma reveals specific variations 65
Bortezomib: A new pro-apoptotic agent in cancer treatment 64
Brigatinib in the first-line treatment of ALK+ metastatic NSCLC: safety and efficacy 63
A headlight on liquid biopsies: a challenging tool for breast cancer management 60
The application of cancer stem cell model in malignant mesothelioma 60
The Association Between Hepatocellular Carcinoma and Gastrointestinal Adenocarcinoma: Is This a New Syndrome in Patients With Cirrhosis? A Case Series 59
BIBF 1120/nintedanib: A new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer 58
Anti-endothelin drugs in solid tumors 57
Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases? 57
Beyond evidence-based data: Scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma 57
Genomic Profiling of Extensive Stage Small-Cell Lung Cancer Patients Identifies Molecular Factors Associated with Survival 55
HIF-1 is involved in the negative regulation of AURKA expression in breast cancer cell lines under hypoxic conditions 52
Cancer and the microbiome: Potential applications as new tumor biomarker 51
Editorial: Cancer biomarkers: molecular insights into diagnosis, prognosis, and risk prediction 45
P3.14.06 Attitude of Italian Physicians Towards Germline and Somatic Genetic Testing in Pleural Mesothelioma: Preliminary Results of a Nationwide Survey 45
Targeting RET-rearranged non-small-cell lung cancer: Future prospects 45
The Effects of Variant Allele Frequency for EGFR Mutation on Early Tumor Shrinkage and Deepness of Response to Osimertinib in Patients with Metastatic Non-Small Cell Lung Cancer: An Exploratory Analysis 44
The role of cMET in non-small cell lung cancer resistant to EGFR-Inhibitors: Did we really find the target? 44
PD-L1 expression as predictive biomarker in patients with NSCLC: A pooled analysis 42
The long and winding road to useful predictive factors for anti-egfr therapy in metastatic colorectal carcinoma: The KRAS/BRAF pathway 40
Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: A retrospective analysis 40
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients 39
Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement 39
HER2-positive male breast cancer: An update 38
The role of 2D-Shearwave elastography in non invasive portal hypertension diagnosis 37
Effects of anti-miR-182 on TSP-1 expression in human colon cancer cells: There is a sense in antisense? 37
Stabilizing versus destabilizing the microtubules: A double-edge sword for an effective cancer treatment option? 36
Driver mutations and differential sensitivity to targeted therapies: A new approach to the treatment of lung adenocarcinoma 35
Targeted therapies in hepatocellular carcinoma 35
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status 35
Progress with palbociclib in breast cancer: Latest evidence and clinical considerations 34
How to find the Ariadne's thread in the labyrinth of salvage treatment options for metastatic colorectal cancer? 34
Monoclonal antibodies in gastrointestinal cancers 33
New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: Do all roads lead to RAS? 33
Ramucirumab and its use in gastric cancer treatment 33
Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies: A literature-based meta-analysis 32
Molecular target therapy for bone metastasis: Starting a new era with denosumab, a RANKL inhibitor 32
Hypoxia and human genome stability: Downregulation of BRCA2 expression in breast cancer cell lines 32
Studio pilota sul valore predittivo dei livelli plasmatici di 9 fattori angiogenetici nella selezione di pazienti candidati alla biopsia prostatica 32
Epithelial-to-mesenchymal transition in the context of epidermal growth factor receptor inhibition in non-small-cell lung cancer 31
Is Ki67 still a powerful ally in predicting the clinical benefit of anthracyclines for the adjuvant treatment of early breast cancer? 30
Semi-automated volumetric analysis in the NELSON trial for lung cancer screening: Is there room for diagnostic experience yet 30
Dietary restriction: could it be considered as speed bump on tumor progression road? 30
MicroRNAs in Colorectal Cancer Drug Resistance: Shooters become Targets 30
Case Report: Stevens-Johnson Syndrome and Hepatotoxicity Induced by Osimertinib Sequential to Pembrolizumab in a Patient With EGFR-Mutated Lung Adenocarcinoma 30
Well-being among Italian medical oncologists: An exploratory study 30
The role of microRNAs in cancer: Diagnostic and prognostic biomarkers and targets of therapies 29
Role of liquid biopsy in oncogene-addicted non-small cell lung cancer 29
The Interplay Between Programmed Death Ligand 1 and Vimentin in Advanced Non-Small-Cell Lung Cancer 29
Multisciplinary management of patients with liver metastasis from colorectal cancer 28
The molecular changes driving the carcinogenesis in Barrett's esophagus: Which came first, the chicken or the egg? 28
What to look for in cell-free DNA from breast cancer patients 28
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? 28
Liquid biopsy for egfr mutation analysis in advanced non-small-cell lung cancer patients: Thoughts drawn from a real-life experience 28
Prognostic vs predictive molecular biomarkers in colorectal cancer: Is KRAS and BRAF wild type status required for anti-EGFR therapy? 27
Epithelial-to-mesenchymal transition and EGFR status in NSCLC: The role of vimentin expression 27
Immunotherapy: Is a minor god yet in the pantheon of treatments for lung cancer? 27
New generation anaplastic lymphoma kinase inhibitors 25
What links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatment 25
Management of toxicity induced by anti-EGFR therapy in metastatic colorectal cancer 24
Immunotherapy for recurrent ovarian cancer: A further piece of the puzzle or a striking strategy? 24
What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis 23
Monoclonal antibodies and antibody fragments: State of the art and future perspectives in the treatment of non-haematological tumors 23
Totale 5.505
Salva come PNG Salva come JPEG
Categoria #
all - tutte 37.139
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 37.139
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202212 0 0 5 0 2 0 0 0 1 0 2 2
2022/20235 1 0 1 0 1 0 0 0 0 0 1 1
2023/2024177 0 0 0 3 1 3 1 4 22 7 11 125
2024/20251.303 40 104 41 19 212 250 21 46 101 246 107 116
2025/20263.777 180 137 239 240 435 111 259 251 435 603 460 427
2026/2027657 216 252 189 0 0 0 0 0 0 0 0 0
Totale 5.985